BlackRock, Novo Nordisk A/S, Apollo Global Management, Black Diamond Therapeutics, and Blackstone are the five Growth stocks ...

Chinese-based Innovent Biologics and HUTCHMED are eyeing approval for their cancer combination after a joint Phase II/III ...

Dr. Sara M. Tolaney discussed HER2-positive breast cancer, highlighting key trials, evolving treatment strategies, and the ...

Moffitt Cancer Center researchers have discovered a promising new vaccine strategy for treating a specific type of breast ...

ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

Servier announces a strategic worldwide licensing agreement for Black Diamond Therapeutics' BDTX-4933 for solid tumors for an ...

B. Riley initiates coverage on ArriVent Biopharma, citing firmonertinib's potential in NSCLC. The analyst sees strong upside with a $37 price target.

Brain tumors remain the most common cause of death from childhood cancer. Paediatric high-grade gliomas (pHGG) in particular are a mostly fatal disease group with a median survival time of less than ...

Investment analysts at HC Wainwright lowered their FY2028 earnings estimates for Gossamer Bio in a research note issued on ...

SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO® in MET-high lung cancer, representing a ...

Johnson & Johnson announced that new data from its oncology pipeline will be presented at the 2025 European Lung Cancer Congress, including ...

Researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer. The innovative approach targets human epidermal growth factor receptor 2-positive, estrogen ...